<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02286804</url>
  </required_header>
  <id_info>
    <org_study_id>ULT-301</org_study_id>
    <nct_id>NCT02286804</nct_id>
  </id_info>
  <brief_title>Ultherapy for the Treatment of Spider Veins on the Legs</brief_title>
  <official_title>Evaluation of the Ulthera® System for Efficacious and Safe Treatment of Leg Telangiectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ulthera, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 30 enrolled subjects will be treated. Enrolled subjects will receive Ultherapy®
      treatments along each length of the spider vein. Follow-up visits will occur at 30 and 60
      days post-treatment. Study images will be obtained pre-treatment, immediately post-treatment,
      and at each follow-up visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single center, clinical trial to be conducted at one clinical
      site. Enrolled subjects will receive up to three Ultherapy® treatments at a single depth, 14
      days apart, using a 10-1.5mm transducer. Treatment will be provided along each length of the
      spider vein and up to four veins will be treated per subject Maximum length of each vein
      treated is 2cm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Improvement of leg telangiectasia was determined by a masked, qualitative assessment of 2D photographs compared to baseline.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of leg telangiectasia</measure>
    <time_frame>60 days post-treatment</time_frame>
    <description>Determined by a masked, qualitative assessment of 2D photographs compared to baseline, based on level of clearance/improvement. Level of improvement scale:
0 = 0% Improvement (None)
1 = &lt; 25% Improvement (Mild)
2 = 26 to 50% Improvement (Moderate)
3 = 51 to 75% Improvement (Significant)
4 = 76 to 100% Improvement (Very Significant)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinician assessment of overall aesthetic improvement</measure>
    <time_frame>30 days post-treatment</time_frame>
    <description>Overall aesthetic improvement will be assessed using the Global Aesthetic Improvement Scale:
Very Much Improved: Optimal cosmetic result in this subject.
Much Improved: Marked improvement in appearance from the initial condition, but not completely optimal for this subject.
Improved: Obvious improvement in appearance from initial condition, but a re-treatment is indicated.
No Change: The appearance is essentially the same as the original condition.
Worse: The appearance is worse than the original condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician assessment of overall aesthetic improvement</measure>
    <time_frame>60 days post-treatment</time_frame>
    <description>Overall aesthetic improvement will be assessed using the Global Aesthetic Improvement Scale:
Very Much Improved: Optimal cosmetic result in this subject.
Much Improved: Marked improvement in appearance from the initial condition, but not completely optimal for this subject.
Improved: Obvious improvement in appearance from initial condition, but a re-treatment is indicated.
No Change: The appearance is essentially the same as the original condition.
Worse: The appearance is worse than the original condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject assessment of overall aesthetic improvement</measure>
    <time_frame>30 days post-treatment</time_frame>
    <description>Overall aesthetic improvement will be assessed using the Global Aesthetic Improvement Scale:
Very Much Improved: Optimal cosmetic result in this subject.
Much Improved: Marked improvement in appearance from the initial condition, but not completely optimal for this subject.
Improved: Obvious improvement in appearance from initial condition, but a re-treatment is indicated.
No Change: The appearance is essentially the same as the original condition.
Worse: The appearance is worse than the original condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject assessment of overall aesthetic improvement</measure>
    <time_frame>60 days post-treatment</time_frame>
    <description>Overall aesthetic improvement will be assessed using the Global Aesthetic Improvement Scale:
Very Much Improved: Optimal cosmetic result in this subject.
Much Improved: Marked improvement in appearance from the initial condition, but not completely optimal for this subject.
Improved: Obvious improvement in appearance from initial condition, but a re-treatment is indicated.
No Change: The appearance is essentially the same as the original condition.
Worse: The appearance is worse than the original condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>30 days post-treatment</time_frame>
    <description>Subjects will rate their satisfaction with the outcome of their treatment based on completion of a patient satisfaction questionnaire using the following scale:
Very Satisfied
Satisfied
Slightly Satisfied
Neither Satisfied or Dissatisfied
Dissatisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>60 days post-treatment</time_frame>
    <description>Subjects will rate their satisfaction with the outcome of their treatment based on completion of a patient satisfaction questionnaire using the following scale:
Very Satisfied
Satisfied
Slightly Satisfied
Neither Satisfied or Dissatisfied
Dissatisfied</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Telangiectasia</condition>
  <condition>Spider Veins</condition>
  <arm_group>
    <arm_group_label>Ultherapy treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving Ultherapy treatment to up to 4 spider veins</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultherapy</intervention_name>
    <description>Micro-focused ultrasound energy delivered below the surface of the skin</description>
    <arm_group_label>Ultherapy treatment</arm_group_label>
    <other_name>Ulthera System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, age 18 years or older.

          -  Subject in good health.

          -  Fitzpatrick Skin Types I-III.

          -  Understands and accepts the obligation not to undergo any other elective procedures,
             i.e., laser and IPL, in the areas to be treated through the follow-up period.

          -  Has up to 4 separate spider veins measuring up to 2 cm in length at a depth of
             approximately 1.0mm.

          -  Has lower extremity spider veins ≤1.0mm in diameter, linear or branching, and red,
             pink, blue and/or purple in color, as assessed by the Investigator.

          -  Willingness and ability to comply with protocol requirements, including returning for
             follow-up visits and abstaining from exclusionary procedures for the duration of the
             study.

          -  Subjects of childbearing potential must have a negative urine pregnancy test result
             and must not be lactating at the Screening Visit and be willing and able to use an
             acceptable method of birth control (e.g. barrier methods used with a spermicidal
             agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study.
             Women will not be considered of childbearing potential if one of the following
             conditions is documented on the medical history:

               1. Postmenopausal for at least 12 months prior to study;

               2. Without a uterus and/or both ovaries; or

               3. Bilateral tubal ligation at least six months prior to study enrollment.

          -  Absence of physical or psychological conditions unacceptable to the investigator.

          -  Willingness to refrain from use of aspirin, Ibuprofen, Naproxen or any other NSAID
             prior to each study treatment and chronic use during the entire post-treatment study
             period. Washout period, if chronic user, for 4 weeks prior to the first treatment.
             Washout period for limited acute NSAID use, i.e., a maximum of 2-3 doses, is required
             in the 2 weeks prior to any study treatment visit.

          -  Willingness and ability to provide written consent for study-required photography and
             adherence to photography procedures (i.e., removal of jewelry and makeup).

          -  Willingness and ability to provide written informed consent and HIPAA authorization
             prior to performance of any study-related procedure

        Exclusion Criteria:

          -  Presence of an active systemic or local skin disease that may affect wound healing.

          -  Presence of significant varicosities or perforator veins in the area(s) to be treated.

          -  Presence of large torturous varicose veins in the area(s) to be treated.

          -  Significant scarring in the area(s) to be treated.

          -  Open wounds or lesions in the area(s) to be treated.

          -  Active implants or metallic implants in the treatment areas.

          -  Presence of underlying metal hardware attached to bone from previous surgeries.

          -  Inability to understand the protocol or to give informed consent.

          -  BMI equal to or greater than 30.

          -  History of chronic drug or alcohol abuse.

          -  History of diabetes.

          -  History of keloid scarring, hypertrophic scarring or abnormal wound healing.

          -  History of immunosuppression/immune deficiency disorders or currently using
             immunosuppressive medications.

          -  History of thromboembolic disease, such as deep vein thrombosis (DVT).

          -  History of autoimmune disease.

          -  Concurrent therapy that, in the investigator's opinion, would interfere with the
             evaluation of the safety or efficacy of the study device.

          -  Subjects who anticipate the need for surgery or overnight hospitalization during the
             study.

          -  Subjects who, in the investigator's opinion, have a history of poor cooperation,
             noncompliance with medical treatment, or unreliability.

          -  Concurrent enrollment in any study involving the use of investigational devices or
             drugs.

          -  Current smoker or history of smoking in the last five years.

          -  History of using the following prescription medications:

               1. Accutane or other systemic retinoids within the past six months;

               2. Antiplatelet agents/Anticoagulants (Coumadin, Heparin, Plavix);

               3. Chronic use of non-steroidal anti-inflammatories (naproxen, ibuprofen, etc.)
                  within the past 4 weeks;

               4. Psychiatric drugs that in the investigators opinion would impair the subject from
                  understanding the protocol requirements or understanding and signing the informed
                  consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Misell, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ulthera, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ulthera, Inc.</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <disposition_first_submitted>December 13, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>December 18, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 19, 2017</disposition_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

